Basic Mechanisms to Clinical Cure 1998
E-Book, Englisch, 507 Seiten, eBook
ISBN: 978-94-011-4882-5
Verlag: Springer Netherland
Format: PDF
Kopierschutz: 1 - PDF Watermark
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
Section I. Helicobacter pylori — THE ORGANISM.- 1 New Helicobacter species.- 2 The origin of virulence in type I strains of Helicobacter pylori.- 3 vacA polymorphism.- 4 The interaction of cag+Helicobacter pylori strains with their hosts.- 5 Molecular mimicry between Helicobacter pylori and the host.- 6 Considerations of virulence by Helicobacter pylori.- Section II. Helicobacter pylori — TRANSMISSION.- 7 The faecal—oral route — a critical look.- 8 Helicobacter pylori: oro—oral, oro—gastric transmission: a critical look at the evidence.- 9 Vectors for the transmission of Helicobacter pylori.- Section III. Helicobacter pylori — INFLAMMATION.- 10 The host cell response to Helicobacter pylori attachment.- 11 Changes in intracellular signalling following Helicobacter pylori infection of gastric epithelial cells.- 12 Helicobacter pylori — interactions with phagocytes.- 13 Th1/Th2 lymphocyte responses in Helicobacter infections.- 14 Epithelial cell turnover and apoptosis.- 15 Cytokine-enhanced, Helicobacter pylori-induced, epithelial cell apoptosis.- Section IV. Helicobacter pylori — FUNCTIONAL SECRETORY AND MOTOR DISTURBANCES.- 16 Acid-adaptive mechanisms of gastric Helicobacter.- 17 Helicobacter pylori and gastroduodenal secretions.- 18 Relevant factors in regulating endocrine, parietal and chief cells.- 19 Histamine and Helicobacter pylori: are we closer to the answer?.- 20 The effect of Helicobacter pylori on enterochromaffin-like (ECL) cell function.- 21 Mast cells and duodenal bicarbonate secretion.- 22 The impact of Helicobacter pylori infection on gastric neuromuscular function in the rat: basic observations and clinical implications for our understanding of functional dyspepsia.- Section V: Helicobacter pylori — PATHOLOGICAL ASPECTS.- 23 Whatdrives the pattern of activity of the inflammatory reaction? Differences in antrum and corpus.- 24 Defining atrophic gastritis and grading gastric atrophy: new challenges beyond the Sydney System.- 25 Cardia mucosa gastritis (carditis): pathogenesis, correlation with gastritis of other sites and clinicopathological relevance.- Section VI: CLINICAL ASPECTS OF Helicobacter pylori INFECTION.- 26 Helicobacter pylori and non-ulcer dyspepsia — a critical look.- 27 Implications of Helicobacter pylori: ‘test-and-treat’ approach in a primary-care setting.- 28 Prerequisites of an adequate approach to dyspepsia: differences between the west and the east.- 29 The Helicobacter pylori—non-steroidal anti-inflammatory drug interaction: consensus at last?.- 30 Helicobacter pylori infection and coronary heart disease: a critical look.- 31 Pitfalls in Helicobacter pylori diagnosis.- Section VII. Helicobacter pylori-ASSOCIATED GASTRIC CANCER AND LYMPHOMA.- 32 An overview of Helicobacter pylori epidemiology studies.- 33 Nitrogen oxides and the gastric precancerous process.- 34 Helicobacter pylori-associated gastric cancer: is population-based screening and therapy realistic?.- 35 Gastric carcinogenesis: when is the point of no return?.- 36 Atrophy, metaplasia and dysplasia — a risk for gastric cancer: are they reversible?.- 37 Lessons from ongoing intervention studies.- 38 Criteria for the diagnosis of mucosa-associated lymphoid tissue lymphoma.- 39 Early and long-term results of Helicobacter pylori cure of MALT lymphoma — what are the pitfalls?.- Section VIII. Helicobacter pylori — TREATMENT ISSUES.- 40 Nitroimidazole metabolism and resistance in Helicobacter pylori.- 41 Bioavailability of antimicrobials after oral and parenteral administration.- 42 Antimicrobial resistancein Helicobacter pylori: a global overview.- 43 Does bismuth prevent antimicrobial resistance of Helicobacter pylori?.- 44 Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis.- 45 Novel therapies for Helicobacter pylori eradication.- 46 Towards monotherapy — what progress? First results with a new single ‘triple’ capsule.- 47 Towards vaccination: what progress?.- Section IX. THE FUTURE OF Helicobacter pylori RESEARCH.- 48 The future of Helicobacter pylori research: the agenda for microbiologists.- 49 The future of Helicobacter pylori research: the agenda for histopathologists.- 50 Helicobacter pylori: the clinical agenda.